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ABSTRACT
OPTIMIZING ANESTHESIA PROVIDERS’ TIMING OF ADMINISTRATION OF
DEXAMETHASONE FOR THE PREVENTION OF POST-OPERATIVE
NAUSEA AND VOMITING: TRANSLATING CLINICAL
GUIDELINES INTO PRACTICE
by Tanner Young Mixon
December 2016
Research has shown that post-operative nausea and vomiting (PONV) is a
significant contributing factor to extended recovery times and unwanted hospital
admissions following ambulatory surgery. The purpose of this DNP project was to assess
current practice regarding administration of dexamethasone for the prevention of PONV,
provide information based on best practice guidelines, and assess willingness to change
practice based on the guidelines set forth by the Society for Ambulatory Anesthesia
(SAMBA). Administration of dexamethasone is aimed at decreasing the incidence of
PONV, optimizing PACU times, and increasing patient satisfaction regarding
perioperative care.
An electronic presentation and survey were emailed to members of the
Mississippi Association of Nurse Anesthetists (MANA) for the purpose of educating
anesthesia providers about current evidence guiding PONV prevention as well as assess
current practice of members. Results were analyzed using descriptive statistics. The
majority of CRNAs surveyed were found to administer dexamethasone in accordance
with the guidelines set forth by SAMBA. It was also found that the CRNAs surveyed
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displayed a willingness to change their current practice when provided with an evidencebased alternative aimed at optimizing patient outcomes.
The results in combination with the guidelines set forth by the Society for
Ambulatory Anesthesia were used to make recommendations meant to improve patient
outcomes following surgery. These recommendations were disseminated to members of
The Mississippi Association of Nurse Anesthetists (MANA) through email as well as the
MANA website.
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CHAPTER I – INTRODUCTION
Statement of Problem
Post-operative nausea and vomiting (PONV) is a very real concern for both
patients and healthcare providers in the ambulatory surgical setting. According to
Butterworth, Mackey, and Wasnick (2013), 1 in every 4 patients will develop postoperative nausea and vomiting (PONV) if not prophylactically treated with an antiemetic. Multiple studies have shown the significant role PONV plays in recovery from
surgery. Researchers found that PONV is a significant contributing factor to extended
recovery times and unwanted hospital admissions following ambulatory surgery (Fortier,
Chung, & Su, 1998). A follow up study in 2013 found similar results linking PONV to
unwanted hospital admissions following day surgery (Whippey et al., 2013). Research
has shown that avoiding PONV outranks even pain among patients asked about their
concerns following surgery (Eberhart, Morin, Wulf, & Geldner, 2002; Gan & Habib,
2016; Lee, Gin, Lau, Dip, & Ng, 2004). PONV is stressful and disruptive to the patient
on a personal level, as well as costly to both the patient and facility. According to Gan
and Habib (2016), patients are willing to spend between $73 and $100 of their own
money to avoid PONV.
Statement of Purpose
While there are a number of clinical tools and guidelines available to assess the
risk and guide treatment of post-operative nausea and vomiting, research suggests
varying practices amongst anesthesia providers in relation to pretreating a patient at risk
for post-operative nausea and vomiting (Smith, Smith, & Smith, 2012). Further, it has
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been demonstrated that the timing of administration of dexamethasone can play a
significant role in preventing PONV (Zou, Jiang, Xiao, & Zhou, 2014).
The purpose of this DNP project was to assess current practice regarding
administration of dexamethasone for the prevention of PONV, provide information based
on best practice guidelines, and assess willingness to change practice based on the
guidelines set forth by The Society for Ambulatory Anesthesia (SAMBA). The results in
combination with the guidelines set forth by SAMBA (Gan et al., 2014) were used to
make recommendations meant to improve patient outcomes following surgery.
Administration of dexamethasone is aimed at decreasing the incidence of PONV
postoperatively, optimizing PACU times and increasing patient satisfaction regarding
perioperative care.
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CHAPTER II – REVIEW OF LITERATURE
Current Guidelines
Gan et al. (2014) formed a multidisciplinary panel under the guidance of The
Society for Ambulatory Anesthesia for the purpose of setting general guidelines directing
the use of antiemetics for the prevention of PONV. The panel determined a single 4 to
5mg dose of dexamethasone at or before induction effectively reduces PONV as well as
increases the quality of recovery after being discharged (Gan et al., 2014). In addition to
directing the administration of dexamethasone, the guidelines suggest a set of patientspecific risk factors to help determine which patients are best suited for prophylactic
treatment of PONV. Significant individual risk factors include being female, less than 50
years old, a history of PONV or motion sickness, and being a non-smoker as can be
found in Table 1. The presence of one or more risk factors increases the risk of PONV
(Gan et al., 2014).
Table 1 PONV Risk Factors
Clinically Significant Risk Factors Contributing to PONV


Female



History of PONV or motion sickness



Nonsmoker



Age less than 50 years old



General anesthesia versus regional block



Use of anesthetic gas (volatile and nitrous oxide)



Use of opioids for postoperative pain control



Duration of anesthetic



Type of surgery (abdominal and gynecological)

Adapted from the guidelines set forth by Gan et al. (2014)
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Gan and Habib (2016), who helped author the consensus guidelines published in
2014, recently published a book guiding the treatment of PONV. The authors continue to
recommend the administration of a single 4-5mg dose of dexamethasone before or
immediately after induction. It is noted that perineal burning, a well-known side effect of
IV dexamethasone, limits its use pre-induction. Gan and Habib (2016) suggest the same
level of PONV prophylaxis exists if dexamethasone is given immediately after induction.
Dexamethasone induced hyperglycemia is seen as one of the only possible sources of
postoperative complications, due to an increased risk for post-operative infection and
delayed wound healing. The authors offer that a single dose approach, and using the
suggested 4-5mg versus the popular dose of 8mg mitigates the risk of these complications
(Gan & Habib, 2016).
Tarantino et al. (2015) performed a randomized, double-blind, placebo-controlled
trial over two years. Patients were assessed for the presence of PONV for 48 hours
following surgery. The researchers found there to be a 28% reduction in absolute risk of
PONV when patients were given a single 8mg dose of dexamethasone preoperatively
compared to a placebo. Though the 8mg dose is associated with an increased blood
glucose level post-operatively, a recent study (Doyle, 2015) suggests 4mg to be as
effective at preventing PONV while allowing for the possibility of a dose dependent
decrease in the hyperglycemic response. In a similar study, Azeem, Ullha, Nasim, and
Cheema (2015) considered patients undergoing laparoscopic cholecystectomy. Patients
were monitored 24 hours following surgery for the presence of PONV. Results showed
PONV in 17% of those receiving dexamethasone and 53% of those receiving a placebo.
It was noted that no adverse effects were observed. Eftekharian and Roozbahany (2011)
4

and Zou et al. (2014) both reported similar findings, noting dexamethasone was most
affective at reducing the incidence of PONV when given at or before induction of
anesthesia.
Patient Significance
PONV is a significant factor contributing to unwanted hospital admissions
following what were scheduled as ambulatory surgeries (Fortier et al., 1998; Whippey et
al., 2013). Gan and Habib (2016) also point to PONV as a significant contributor to
extended post anesthesia care unit (PACU) stays as well as unwanted hospital
admissions, noting that each occurrence of emesis adds an estimated 20 minutes to the
PACU stay. While an exact number is hard to calculate, it is estimated that extra costs
related to PONV and post-discharge nausea and vomiting (PDNV) amount to several
million US dollars annually (Gan & Habib, 2016). Unexpected overnight admissions to
the hospital can lead to further disruption for the patient in regards to their time and
recovery. Each extra day spent in the hospital increases the chance of infection by up to
1.37% (Hassan, Tuckman, Patrick, Kountz, & Kohn, 2010). According to a study by De
Lissovoy et al. (2009) looking at 723,490 patients hospitalized due to surgery, a single
surgical site infection extended the length of hospital stay by an average of 9.7 days.
Extended recovery times and increased risk of unwanted hospital admission following
ambulatory surgery can mean time away from work and lost wages. This also increases
the time it takes a patient to return to their normal level of activity (Gan & Habib, 2016).
While unexpected admissions and infection rates are straightforward to measure, patient
satisfaction is more subjective in nature.
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Odom-Forren et al. (2014) reported in a 2014 study that patients exhibiting PONV
and PDNV reported a decreased quality of life until symptoms resolved. The authors also
found PONV and PDNV to affect the patient’s ability to eat and drink, perform normal
daily activities, and sleep for up to a week after discharge following ambulatory surgery.
Patient satisfaction with their treatment was found to be negatively affected by the
presence of PONV and PDNV (Odom-Forren et al., 2014). White et al. (2008) also
reported that PONV interfered with a patient’s level of function in regards to their
appetite and ability to sleep, both of which play a vital role in a patient’s recovery from
surgery. In a study by Eberhart et al. (2002), patients were asked questions related to their
concerns regarding recovery from surgery. The authors concluded PONV ranked highest,
even outranking pain, when it came to what the patients were most worried about in the
immediate postoperative period (Eberhart et al., 2002). Gan and Habib (2016) report
similar findings, stating patients fear PONV at a higher rate than pain and shivering.
Facility Significance
Fortier et al. (1998) determined PONV to be a significant factor contributing to
14.4% of unwanted hospital admissions following ambulatory surgery. A more recent
study (Whippey et al., 2013) found similar results further pointing to PONV as an
important and modifiable risk factor relating to delayed recovery from surgery. As stated
before, each occurrence of emesis can increase PACU stay times by about 20 minutes
(Gan & Habib, 2016). According to Raft, Millet, and Meistelman (2014), in 2012 the
average cost for a stay in the PACU was estimated to be $12 per minute, which would
equal $240 per episode of emesis. Another study conducted by Habib, Chen, Taquchi,
Hu, and Gan (2006) linked emesis to significantly increased use of resources, requiring
6

the nurse’s full attention and the use of rescue anti-emetics, as well as increased PACU
times up to 25 minutes per episode and associated costs of $138. In contrast, the
pharmacy at a trauma center located in Mississippi indicated that the cost of a single 4mg
vial of dexamethasone cost around $2.50. Unexpected hospital admissions can also
contribute significantly to cost for facilities considering that as of 2014, the average cost
of one inpatient day at a hospital in Mississippi was $1351 (The Henry J. Kaiser Family
Foundation, n.d.). According to Zimlichman et al. (2013), the cost of a single surgical site
infection in 2012 was around $20,000 and totaled $3.3 billion in the US for the year,
reflecting what De Lissovoy et al. (2009) found in an earlier study looking at how
surgical site infections affect the cost of healthcare.
Patient satisfaction scores can be factored into reimbursement rates, showing the
importance of optimizing a patient’s perioperative experience. Hocking, Weightman,
Smith, Gibbs, and Sherrard (2013) reported PONV as the source of 9% of the variance in
patient’s perceptions of the quality of anesthesia provided to them. In a study analyzing
perioperative factors affecting HCAHPS responses of 2,758 surgical patients, Maher et
al. (2015) found pre-operative and post-operative experiences to be the largest
contributing factors to how patients ranked their encounter, lending to the importance of
the post-operative experience and its effect on patient satisfaction scores. Eberhart et al.
(2002) determined PONV to be the most significant concern for patients in the immediate
postoperative period, suggesting anesthesia providers pay close attention to the
prevention of PONV. White, O’Hara, Roberson, Wender, and Candiotti (2008) found
PONV led to a reduction in appetite as well as sleep following surgery, further pointing
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to the importance of preventing PONV in relation to patient outcomes and patient
satisfaction scores as determinants of reimbursement.
Summation of the Literature
Based on the review of current literature, there exists a large body of evidence in
support of using dexamethasone as an antiemetic. Consensus guidelines (Gan et al.,
2014) point to dexamethasone as an effective and inexpensive prophylactic treatment for
PONV. Further, it is a medication with few side effects which can be minimized through
optimal dosage and timing of administration (Gan & Habib, 2016).
PONV is an important factor related to patient recovery. Both White et al. (2008)
and Odom-Forren et al. (2014) found PONV and PDNV to negatively affect a patient’s
post-operative experience and delay the return to normal day-to-day activities, pointing to
prevention of PONV as an important part of recovery from surgery. Post-operative
experience and PONV also plays an important role in patient satisfaction scores (Maher
et al., 2015), which can negatively affect reimbursement based on patients’ perception of
the quality of anesthesia provided (Hocking et al., 2013). PONV can also directly affect
cost of care through increased PACU times (Gan & Habib, 2016) and increased resource
usage (Habib et al., 2006). Each episode of emesis from PONV in the PACU has been
estimated to cost up to $240 dollars (Raft et al., 2014).
Conclusion
While each of the studies above presents different levels of effectiveness and
significance, they all suggest that there is potential value in the use of dexamethasone as a
cost effective, safe, and reliable prophylactic treatment for post-operative nausea and
vomiting aimed at improving patient outcomes. More importantly, the aforementioned
8

studies support the current guidelines set forth by the Society for Ambulatory Anesthesia
(Gan et al., 2014).
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CHAPTER III - METHODOLOGY
Target Outcomes
The planned outcomes of this DNP project were to:
1. Assess current practice among CRNAs related to the use of dexamethasone
for preventing PONV and
2. Provide an educational presentation of the guidelines set forth by the Society
for Ambulatory Anesthesia and supporting evidence regarding the prevention
of PONV using dexamethasone and
3. Assess CRNA willingness to change current practice based on the evidence
presented.
Theoretical Framework
The focus of this project follows the goals outlined by the Model for Change to
Evidence-Based Practice as proposed by Rosswurm and Larrabee (1999). This theoretical
framework describes a process that calls for assessing whether there is a need for a
change in practice, linking the need with specific interventions and patient outcomes,
compiling evidence, creating a plan for changing the current practice, implementing and
evaluating the change, then merging the change with current standards so as to maintain
the new standard as proposed by the findings of the study (Rosswurm & Larrabee, 1999).
The proposed theoretical framework provides a tested and trusted guide for evaluating
and implementing change in practice if indicated. It also provides for the future
implementation of the aforementioned guidelines if indicated by the findings of this DNP
project. Due to the limited time frame available, this capstone project utilized the first
four steps outlined by Rosswurm and Larrabee (1999): assessing the need for change,
10

linking the need with specific interventions and outcomes, compiling the evidence, and
creating a plan for changing the current practice.
Target Population
The target population was practicing CRNAs that are current members of the
Mississippi Association of Nurse Anesthetists (MANA). MANA members include 500600 CRNAs working in a variety of different clinical settings throughout the state of
Mississippi. Inclusion criteria was limited to licensed CRNAs currently practicing in the
perioperative setting in Mississippi and participants must be at least 18 years of age. All
other survey participants were excluded.
Setting
The DNP project utilized MANA membership. Data was collected from CRNAs
licensed and working in the state of Mississippi, and results from the project were
disseminated to the association for the purpose of improving patient outcomes. The
MANA membership reflects CRNAs working in settings covering the full spectrum of
clinical practice, including rural hospitals, ambulatory surgery centers, office based
practice, as well as trauma centers throughout Mississippi.
Design
The DNP project assessed the current practice of CRNAs using dexamethasone
for the prevention of PONV. MANA members were sent a short presentation outlining
current guidelines set forth by the Society for Ambulatory Anesthesia (Gan et al., 2014)
as well as supporting evidence-based on the review of literature. The educational
presentation can be found in Appendix C. In addition, a link to a short survey was
provided. Questions covered familiarity with the current guidelines set forth by the
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Society for Ambulatory Anesthesia, preferred dosage (4mg, 8mg, other), preferred timing
of administration (pre-induction, during or immediately after induction, immediately
before emergence), whether they felt their current practice is effective, and willingness to
change current practice if provided with an evidence-based alternative. Demographic data
including sex, age, and years of practice was also gathered. The survey tool can be found
in Appendix D.
Survey data remained completely anonymous, and was only used for study
purposes and analysis based on the stated target outcomes. Participation in the survey was
completely voluntary and posed no risk to those choosing to do so. In addition,
participants were provided with an educational opportunity aimed at optimizing their
current practice. Subjects were chosen based on their willingness to participate using a
convenience sample, this type of sampling allowed for access to a large number of
practicing CRNAs in Mississippi and helped to maximize survey participation. Survey
responses were collected using a password protected account provided by the online
survey tool Qualtrics. Survey data was stored on a personal computer for the purposes of
analysis and interpretation. The personal computer and its contents were password
protected for the duration of the study, after which survey data was removed. At no time
was identifiable information collected or stored for the purposes of the DNP project.
Following data analysis, MANA was presented with findings and
recommendations based on current guidelines set forth by SAMBA and supporting
evidence to help improve patient outcomes if indicated by the results of the survey.
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Procedure
Following University of Southern Mississippi (USM) Institutional Review Board
(IRB) approval, an electronic survey developed using the online tool Qualtrics provided
by USM, and an electronic presentation outlining the current guidelines set forth by
SAMBA (Gan et al., 2014) and supporting evidence was emailed to members of MANA.
Procedures for data collection were as follows:
1. An email containing two anonymous links was sent to all MANA members
through MANA's membership email list. The first link allowed participants to
view the electronic presentation outlining current literature and guidelines.
The second link provided access to the electronic survey administered through
the online survey tool Qualtrics.
2. Participants were then asked to review the electronic presentation first,
followed by completion of the electronic survey. Participants were given two
weeks to complete the survey starting from the date the email was delivered.
A reminder email was sent when one week remained in the survey period.
3. After the survey period of two weeks had passed, the survey was closed.
4. Data was then compiled and analyzed.
Data Analysis
Results were analyzed using descriptive statistics utilizing frequency tables for the
purpose of determining if and how CRNAs within MANA were using dexamethasone for
the purpose of preventing PONV. Knowing how CRNAs administer dexamethasone can
help to guide future efforts aimed at educating CRNAs on preventing PONV. Results
were compared to the most recent guidelines set forth by SAMBA and the supporting
13

evidence found within the review of literature for the purpose of guiding
recommendations for future practice.
Ethics
The electronic questionnaire was completely anonymous and completed on a
voluntary basis. Participation in this survey and its findings posed no risk to participants,
and analysis of the data focused on optimization of current practice. Any change in
practice or patient care related to the findings of this DNP project was determined by the
anesthesia providers.
Assumptions
The main assumption was that the anesthesia providers surveyed view PONV as
an important and modifiable complication following surgery. It was also assumed that
patient outcomes at the facilities staffed by the CRNAs belonging to MANA can be
improved with the optimization of dexamethasone administration relating to PONV.
Resource Requirements
Few resources were required for this DNP project. Those required included the
University of Southern Mississippi library, access to a computer, access to the internet,
and related books.
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CHAPTER IV – ANALYSIS OF DATA
Results
During the two week survey period, 36 responses were recorded using the online
survey tool Qualtrics. Of those 36 responses, 24 reported they were currently licensed
and practicing CRNAs and 12 reported they were not. Assuming a total membership of
600 as reported by MANA, this represents a total response rate of 6%. For the purposes
of this project, only the 24 participants indicating they were licensed and practicing
CRNAs were used for analysis representing a useable response rate of 4%. 14 of the
participants were male (58.33%), while the remaining 10 participants indicated they were
female (41.67%). Participants ranged in age from 30 to 60 or greater years old, with the
majority of participants (45.83%) reporting between 40 and 49 years old as shown in
Table 2. Regarding work experience, the majority of participants (58.34%) reported
having worked for 10 years or less as a CRNA as shown in Table 3.
Table 2 Question 2
Answer

%

n

18-29

0.00%

0

30-39

33.33%

8

40-49

45.83%

11

50-59

8.33%

2

12.50%

3

100%

24

60 or above
Total

15

Table 3 Question 4
Answer

%

n

0-5

29.17%

7

6-10

29.17%

7

11-15

20.83%

5

16-20

8.33%

2

12.50%

3

100%

24

20 or more
Total

Question 5
When asked about their previous knowledge of the guidelines proposed by
SAMBA for the prevention of PONV, all participants reported being at least slightly
familiar with the guidelines, with 12 participants (50%) being either Very familiar or
Extremely familiar with the guidelines. Six (25.00%) reported being Moderately familiar,
while six (25.00%) reported being Slightly familiar. No participants reported being Not
familiar at all with the guidelines.
Table 4 Question 5
Answer

%

n

Extremely familiar

16.67%

4

Very familiar

33.33%

8

Moderately familiar

25.00%

6

Slightly familiar

25.00%

6

Not familiar at all

0.00%

0

Total

100%

24
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Question 6
When asked how often they administer dexamethasone to prevent PONV, all
participants reported administering dexamethasone at least Sometimes, with 19
participants (79.17%) saying they administer it either Most of the time or Always to help
prevent PONV. Two (8.33%) reported About half the time, and three (12.50%) reported
Sometimes. No participants reported administering dexamethasone Never.
Table 5 Question 6
Answer

%

n

Always

29.17%

7

Most of the time

50.00%

12

8.33%

2

12.50%

3

Never

0.00%

0

Total

100%

24

About half the time
Sometimes

Question 7
Participants were asked about their preferred dosage of dexamethasone for the
prevention of PONV prior to viewing the presentation. 15 participants (62.50%) reported
4 mg was their preferred dosage, reflecting the guidelines set forth by SAMBA on PONV
prevention. Eight participants (33.33%) reported 8 mg was their preferred dosage for
preventing PONV. One participant (4.17%) chose Other, allowing them to write in their
preferred dosage of 12 mg.
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Table 6 Question 7
Answer

%

n

8mg

33.33%

8

4mg

62.50%

15

Other (mg)

4.17%

1

I don't administer dexamethasone to prevent PONV

0.00%

0

Total

100%

24

Question 8
Participants were asked what their preferred dosage of dexamethasone was after
having viewed the provided presentation. 20 participants (83.33%) reported 4 mg would
now be their preferred dosage. Three participants (12.50%) reported they would continue
to administer 8 mg, and one participant (4.17%) reported they would continue to
administer their preferred dosage of 12 mg. This represents an increase of five
participants (20.83%) reporting they will now be administering the recommended dosage
of 4-5 mg of dexamethasone as outlined in the guidelines set forth by SAMBA. This
finding suggests that CRNAs are willing to change their current practice if provided with
an evidence-based alternative.
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Table 7 Question 8
Answer

%

n

8mg

12.50%

3

4mg

83.33%

20

Other (mg)

4.17%

1

I don't administer dexamethasone to prevent PONV

0.00%

0

Total

100%

24

Question 9
When participants were asked during which phase of anesthesia they preferred to
administer dexamethasone to prevent PONV, 20 (83.34%) reported either Pre-induction
or During or immediately after induction. This finding reflects the recommendations in
the guidelines set forth by SAMBA, suggesting that the majority of CRNAs administer
dexamethasone to prevent PONV based on the best evidence currently available. The
remaining four participants (16.67%) reported administering dexamethasone During
maintenance of anesthesia to prevent PONV.
Table 8 Question 9
Answer

%

n

4.17%

1

During or immediately after induction

79.17%

19

During maintenance of anesthesia

16.67%

4

Immediately before or during emergence

0.00%

0

After emergence

0.00%

0

I don't administer dexamethasone to prevent PONV

0.00%

0

Total

100%

24

Pre-induction

19

Question 10
When participants were asked about how effective they feel dexamethasone is at
preventing PONV, seven (29.17%) responded that they feel dexamethasone is
Moderately effective, 13 (54.17%) feel it is Very effective, and four (16.67%) feel it is
Extremely effective. No participants responded that they feel dexamethasone is Not
effective at all at preventing PONV. This finding suggests that CRNAs trust
dexamethasone as an effective preventative treatment for PONV, and administer it for
this purpose.
Table 9 Question 10
Answer

%

n

Extremely effective

16.67%

4

Very effective

54.17%

13

Moderately effective

29.17%

7

Slightly effective

0.00%

0

Not effective at all

0.00%

0

Total

100%

24

Question 11
When participants were asked to rate their willingness to administer
dexamethasone by using the technique as described in the provided presentation based on
the guidelines set forth by SAMBA, 23 (95.83%) responded by saying they were either
Very willing or Extremely willing to do so. One (4.17%) said they were Moderately
willing, and no participants responded they were Not willing at all. This finding suggests
either CRNAs were already administering dexamethasone to prevent PONV using the
technique as described in the provided presentation, or CRNAs are willing to change their
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current practice when provided with an evidence-based alternative aimed at optimizing
patient outcomes.
Table 10 Question 11
Answer

%

n

Extremely willing

45.83%

11

Very willing

50.00%

12

Moderately willing

4.17%

1

Slightly willing

0.00%

0

Not willing at all

0.00%

0

Total

100%
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Discussion
Using the target outcomes of this project as a guide, interpretation of the survey
results reveals several noteworthy findings. By assessing current practice among CRNAs,
it is clear that CRNAs do administer dexamethasone for the purpose of preventing
PONV. Question six shows that 19 participants (79.17%) administer dexamethasone
either Most of the time or Always to help prevent PONV. Question seven shows that 15
participants (62.50%) administer 4 mg of dexamethasone when given to prevent PONV.
Question nine shows that 20 participants (83.34%) reported either Pre-induction or
During or immediately after induction as their preferred time to administer
dexamethasone to prevent PONV. These findings not only suggest that CRNAs
administer dexamethasone to prevent PONV, but also that the majority of CRNAs
surveyed do so using the technique found in the guidelines set forth by SAMBA, which
suggests giving 4 mg of dexamethasone pre-induction, during induction, or immediately
after induction of anesthesia.
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Further analysis of the survey results gives insight into how willing CRNAs are to
change their current practice as well. Question seven and question eight show a
difference exists in CRNAs’ preferred dosage of dexamethasone when comparing
responses prior to viewing the provided presentation and after viewing the presentation.
In accordance with the guidelines set forth by SAMBA, 15 participants (62.50%) gave 4
mg of dexamethasone prior to viewing the presentation. After viewing the presentation,
20 participants (83.33%) reported 4 mg would be their preferred dosage of
dexamethasone for preventing PONV. This finding shows an increase of 5 participants
(20.83%) reporting they will now administer 4 mg of dexamethasone as suggested in the
guidelines set forth by SAMBA. Question 11 shows 23 participants (95.83%) were
willing to administer dexamethasone following the technique outlined in the presentation
and based on the guidelines set forth by SAMBA. The responses to questions seven,
eight, and eleven suggest that the majority of CRNAs surveyed are willing to change
their current practice when provided with an evidence-based alternative aimed at
optimizing patient outcomes.
Limitations
The survey for this project was completed on a voluntary basis, and relied
completely on the CRNAs’ willingness to do so. As such, it is hard to determine whether
the sample is representative of the general population, especially given the small sample
size (n=24) and low total response rate of 6%. While the findings of this project offer
some insight for current CRNA practice, the results are only applicable to the sample
surveyed. Based on the small sample and low response rate, it is also difficult to
determine whether a significant level of correlation exists between survey questions when
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analyzing responses, allowing only for the use of descriptive statistics. This project also
does not take into account how CRNAs use dexamethasone in tandem with other
prophylactic anti-nausea treatments, or how dexamethasone administration may be
affected by alternative measures or disease processes.
Future Practice
The implications of this project are based on the major findings of the survey
results; a majority of CRNAs surveyed administer dexamethasone in accordance with the
guidelines set forth by SAMBA, and a majority of CRNAs surveyed are willing to
change their current practice if presented with an evidence-based alternative aimed at
optimizing patient outcomes. These findings suggest CRNAs are receptive to the most
current evidence-based practices, and are willing to integrate new techniques into their
own practice when trying to optimize patient outcomes. Each of these attributes is
important in ensuring the best possible care is provided to each patient.
While the overall findings are positive, there are several responses indicating a
reluctance to change current practice based on the presentation and evidence provided. It
is impossible to determine reasons for this with the current data set, but future studies can
do so using more in depth surveys as well as sampling from a larger population. By
reaching out to other state nurse anesthesia associations, as well as student registered
nurse anesthetists, a much larger sample can be surveyed in the hope of creating a more
generalizable data set. Future studies should also take into account other aspects of the
guidelines set forth by SAMBA, as dexamethasone is only one small piece of the puzzle
when trying to prevent PONV.
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This capstone project utilized the first four steps outlined by Rosswurm and
Larrabee (1999) in their Model for Change to Evidence-Based Practice: assessing the
need for change through the literature review and survey, linking the need with specific
interventions and outcomes based on the current guidelines, compiling the evidence
through analysis of the current literature and survey results, and creating a plan for
changing the current practice by providing an educational presentation outlining the
current literature and guidelines. Future researchers should aim to utilize the final two
steps in Rosswurm and Larrabee’s process: implementing and evaluating the change and
merging the change with current standards. A retrospective chart review focused on
PONV and dexamethasone administration trends within a facility or region would
provide valuable information allowing for the evaluation of the change in practice, and
whether the current guidelines set forth by SAMBA should be made standard of practice
within the population being studied.
Conclusion
A review of the literature has shown that PONV is a significant contributing
factor to extended recovery times and unwanted hospital admissions following
ambulatory surgery. The findings of this project suggest the majority of CRNAs surveyed
are active participants in utilizing the most current evidence-based practice, and are
willing to integrate new techniques into their own practice with the goal of optimizing
patient outcomes. By continuing to do so, CRNAs are able to play an integral role in
expanding clinical knowledge and improving patient outcomes. While the results of this
project are encouraging, there is certainly a need for future studies to help improve our
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understanding of how CRNAs currently use the resources available to them when trying
to prevent PONV.
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APPENDIX E – DNP Essentials

DNP Essentials

Capstone relation to DNP Essentials

DNP Essentials I – Scientific

This DNP project is centered on the most

underpinnings for practice

current evidenced based guidelines for
using dexamethasone to prevent PONV.
These guidelines were created through
multidisciplinary collaboration, and are
supported by peer-reviewed research.

DNP Essentials II – Organizational and

PONV is a frequent and disruptive part of

systems leadership for quality

the perioperative experience. This DNP

improvement and systems thinking

project is aimed at improving patient
outcomes through the optimized dosage
and timing of dexamethasone
administration for preventing PONV and
was designed as a quality improvement
project.

DNP Essentials III – Clinical

By using Rosswurm and Larrabee’s

scholarship and analytical methods for

Model for Change to Evidence-Based

evidence-based practice

Practice, this DNP project uses a
framework allowing for its use in different
settings for the purpose of assessing
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practice and quality improvement to better
anesthesia practice

DNP Essentials IV – Information

This DNP project required the use of

systems or technology and patient care

electronic databases to perform the review

technology for the improvement and

of literature. An electronic survey and

transformation of health care

educational presentation were also created
for the purpose of gathering data and
educating CRNAs on the most current
guidelines set forth by SAMBA

DNP Essentials V – Healthcare policy

Through its collaboration with MANA

for advocacy in healthcare

and dissemination of results to MANA
members, this DNP project has the
potential to influence future practice and
policy across the state of Mississippi.

DNP Essentials VI – Interprofessional

Through the education of CRNAs

collaboration for improving patient and

regarding dexamethasone’s use as an anti-

population health outcomes

emetic, the CRNAs will be better able to
share their knowledge of PONV
prevention with other healthcare
professionals in the perioperative setting.
This shared knowledge will allow for a
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more seamless transition of care through
the perioperative period.
DNP Essentials VII – Clinical

PONV can cause increased PACU times

prevention and population health for

and delayed recovery following surgical

improving the nation’s health

procedures. This DNP project was aimed
at using dexamethasone prophylactically
to prevent PONV from occurring.

DNP Essentials VIII – Advanced

This DNP project was ultimately aimed at

Nursing Practice

evaluating one’s current practice and
utilizing the most current evidence-based
literature to make clinical decisions for
the purpose of improving patient
outcomes.
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